Drug Trial Radar · NCT00845728
Exacerbation Study
Last checked: Nov 20, 2026Latest source record: Nov 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,439
Actual
Start
Mar 2009
Primary completion
Jul 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 µgDrug
Indacaterol 150 µg o.d. delivered via SDDPI
TiotropiumDrug
Tiotropium 18 µg o.d. delivered via handihaler®
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trough Forced Expiratory Volume in 1 Second (FEV1).Time frame: 12 weeks
Locations
423 sites in 40 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Capital Federal, Buenos Aires, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Novartis Investigative Site
Pilar, Buenos Aires, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, Argentina
Novartis Investigative Site
Tauranga, New Zealand, Australia
Novartis Investigative Site
Bankstown, New South Wales, Australia
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Daw Park, South Australia, Australia
Novartis Investigative Site
Heidelberg, Victoria, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Feldbach, Austria, Austria
Novartis Investigative Site
Gänserndorf, Austria, Austria
Novartis Investigative Site
Grieskirchen, Austria, Austria
Novartis Investigative Site
Hallein, Austria, Austria
Novartis Investigative Site
Linz, Austria, Austria
Novartis Investigative Site
Perg, Austria, Austria
Novartis Investigative Site
Zwettl Stadt, Austria, Austria
Novartis Investigative Site
Aalst, Belgium
Novartis Investigative Site
Antwerp, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Duffel, Belgium
Novartis Investigative Site
Eupen, Belgium
Novartis Investigative Site
Godinne, Belgium
Novartis Investigative Site
Gozée, Belgium
Novartis Investigative Site
Herentals, Belgium
Novartis Investigative Site
Jambes, Belgium
Novartis Investigative Site
Jette, Belgium
Novartis Investigative Site
Kortrijk, Belgium
Showing 40 of 423 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.